JPMorgan Chase & Co. Has Lowered Expectations for BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) had its price target reduced by JPMorgan Chase & Co. from $27.00 to $25.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 172.12% from the company’s current price.

A number of other equities research analysts also recently issued reports on BBOT. Oppenheimer initiated coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 price target on the stock. Canaccord Genuity Group began coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $23.00 target price on the stock. UBS Group downgraded shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a report on Wednesday, July 8th. Wall Street Zen upgraded shares of BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a report on Thursday, June 18th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.40.

BridgeBio Oncology Therapeutics Stock Performance

NASDAQ BBOT traded down $0.04 during trading on Friday, hitting $9.19. 69,585 shares of the company’s stock traded hands, compared to its average volume of 358,610. The stock has a market capitalization of $736.52 million, a price-to-earnings ratio of -3.33 and a beta of 0.36. BridgeBio Oncology Therapeutics has a 12-month low of $7.00 and a 12-month high of $14.87. The business has a 50 day moving average of $8.27 and a 200-day moving average of $9.08.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($705.20) earnings per share for the quarter. On average, analysts expect that BridgeBio Oncology Therapeutics will post -2.3 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. CIBC Private Wealth Group LLC bought a new position in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at $63,000. XTX Topco Ltd grew its stake in shares of BridgeBio Oncology Therapeutics by 22.4% during the fourth quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock valued at $358,000 after buying an additional 5,249 shares during the last quarter. Persistent Asset Partners Ltd bought a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter valued at about $107,000. Tema ETFs LLC increased its holdings in shares of BridgeBio Oncology Therapeutics by 13.6% in the second quarter. Tema ETFs LLC now owns 93,339 shares of the company’s stock worth $711,000 after buying an additional 11,167 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $144,000. 54.89% of the stock is currently owned by institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.